GlaxoSmithKline, a global pharmaceutical and healthcare products manufacturer, plans to close its Carlisle facility in Pennsylvania, USA and move the site’s production to Puerto Rico, the company announced.
GSK spokeswoman Jennifer Albano said the move will impact about 260 employees. The closure of the plant is to happen by the end of next year.
Production will be phased out of the Allen Road facility by mid-2021, with a full exit by the end of 2021, Albano said. The Carlisle site produces consumer healthcare products.
In response to media queries about the closure, the Britain-based corporation responded, “After careful review, GSK has decided to close the Carlisle, PA site to consolidate volumes and generate efficiencies by moving the site’s production to our Guayama, Puerto Rico facility.”
“After careful review, GSK has decided to close the Carlisle, PA site to consolidate volumes and generate efficiencies by moving the site’s production to our Guayama, Puerto Rico facility.”– GlaxoSmithKline
GlaxoSmithKline uses the site to make Emergen-C, a powdered drink mix vitamin C supplement. The production line originally landed in Pennsylvania in 2011, when the product was made by Alacer Corp.
But that was two corporate generations ago. Alacer was acquired by Pfizer in 2012, which placed the company into its consumer healthcare portfolio. Then, in late 2018, Pfizer and GlaxoSmithKline announced plans to merge their consumer health divisions into a new joint venture.
That merger was completed last year, with GlaxoSmithKline owning 68 percent of the new entity, and Pfizer the remainder. By all accounts, the Emergen-C plant has flourished in Carlisle.
When Alacer started operations in Pennsylvania company executives promised the creation of 70 jobs within three years. Yesterday’s announcement of the closure runs concurrent with the expiration of a 10-year lease on the Carlisle site.
Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s seventh largest pharmaceutical company as of 2015, after Johnson & Johnson, Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.